

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
10 June 2010 (10.06.2010)

PCT

(10) International Publication Number
WO 2010/065568 A3

(51) International Patent Classification:
G01N 33/53 (2006.01) G01N 33/48 (2006.01)

(74) Agents: CALKINS, Charles, W. et al.; Kilpatrick Stockton, LLP, 1001 West Fourth Street, Winston-Salem, NC 27101 (US).

(21) International Application Number:
PCT/US2009/066295

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(22) International Filing Date:
1 December 2009 (01.12.2009)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/118,975 1 December 2008 (01.12.2008) US
61/182,282 29 May 2009 (29.05.2009) US
61/187,960 17 June 2009 (17.06.2009) US

(71) Applicant (for all designated States except US): LABORATORY CORPORATION OF AMERICA HOLDINGS [US/US]; 430 South Spring Street, Burlington, NC 27215 (US).

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(72) Inventors; and

(75) Inventors/Applicants (for US only): SPERINDE, Jeff [US/US]; 623 Isabella Road, El Granada, CA 94018 (US). WINSLOW, John, William [US/US]; 931 Ventura Street, El Granada, CA 94018 (US). JIN, Xueguang [CN/US]; 4490 Calypso Terrace, Fremont, CA 94555 (US).


Published:

— with international search report (Art. 21(3))

[Continued on next page]

(54) Title: METHODS AND ASSAYS FOR MEASURING p95 AND/OR p95 IN A SAMPLE AND ANTIBODIES SPECIFIC FOR p95

FIGURE 5a



(57) Abstract: Methods of measuring and/or quantifying the presence and/or amount of p95 and/or p95 complex in a sample utilizing monoclonal antibodies specific for p95 are provided.

WO 2010/065568 A3



— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

(88) Date of publication of the international search report:
22 July 2010

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US 09/66295

A. CLASSIFICATION OF SUBJECT MATTER
 IPC(8) - G01N 33/53, 33/48 (2010.01)
 USPC - 436/501, 63
 According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED
 Minimum documentation searched (classification system followed by classification symbols)
 USPC: 436/501, 63

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched
 USPC: 436/501, 63 (text search)

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
 Electronic data bases searched: PubWEST (EPAB, JPAB, USPT, PGPB); Google Scholar; GenCore Sequence Search (AA)
 Search terms used: p95HER2 (synonyms: p95HER-2, truncated ErbB2, truncated HER2), extracellular "stub" region, antibody, immunoassay, proximity probe, Veritag assay (Etag assay), cancer prognosis (breast, NSCLC), drug resistance, biomarker

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X ----- Y ----- A	US 2003/0059863 A1 (CLINTON). 27 March 2003 (27.03.2003). Especially para [0009]-[0023],[0032], [0058], SEQ ID NO: 1.	1-4, 7-9, 21, 22, 24-27, 30-33 ----- 5, 10-14, 16-19, 23, 28 ----- 6, 15, 20, 29
Y	US 2004/0241686 A1 (NELSON). 2 December 2004 (02.12.2004). Especially SEQ ID NO: 11. 5,14,19, 23, 28	5,14,19, 23,28
Y --- A	HUANG et al. Comparison of Central HER-2 Tests with Quantitative HER-2 Expression and HER-2 Homodimer Measurements Using a Novel Proximity Based Assay. Abstract 40 American College of Pathologist Annual Meeting 25-28 September 2008. Available on the internet: <URL: http://www.hermarkassay.com/publications.aspx >. Especially pg 5, fig 1 and 2.	10-14,16-19 ----- 15, 20
Y	US 2008/0131883 A1 (ADAMS et al.) 5 June 2008 (05.06.2008) abstract, para [0410], [0383]	16
A	XIA et al. Truncated ErbB2 receptor (p95ErbB2) is regulated by heregulin through heterodimer formation with ErbB3 yet remains sensitive to the dual EGFR/ErbB2 kinase inhibitor GW572016. 22 January 2004 Oncogene Vol 23 No 3 Pages 646-653. Especially abstract.	1-33

Further documents are listed in the continuation of Box C.

- | | |
|---|--|
| * Special categories of cited documents: | "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention |
| "A" document defining the general state of the art which is not considered to be of particular relevance | "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone |
| "E" earlier application or patent but published on or after the international filing date | "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art |
| "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) | "&" document member of the same patent family |
| "O" document referring to an oral disclosure, use, exhibition or other means | |
| "P" document published prior to the international filing date but later than the priority date claimed | |

Date of the actual completion of the international search 13 April 2010 (13.04.2010)	Date of mailing of the international search report 25 MAY 2010
---	--

Name and mailing address of the ISA/US Mail Stop PCT, Attn: ISA/US, Commissioner for Patents P.O. Box 1450, Alexandria, Virginia 22313-1450 Facsimile No. 571-273-3201	Authorized officer: Lee W. Young PCT Helpdesk: 571-272-4300 PCT OSP: 571-272-7774
---	--

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 09/66295

Box No. 1 Nucleotide and/or amino acid sequence(s) (Continuation of item 1.c of the first sheet)

1. With regard to any nucleotide and/or amino acid sequence disclosed in the international application, the international search was carried out on the basis of a sequence listing filed or furnished:

a. (means)

- on paper
 in electronic form

b. (time)

- in the international application as filed
 together with the international application in electronic form
 subsequently to this Authority for the purposes of search

2. In addition, in the case that more than one version or copy of a sequence listing has been filed or furnished, the required statements that the information in the subsequent or additional copies is identical to that in the application as filed or does not go beyond the application as filed, as appropriate, were furnished.

3. Additional comments:

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US 09/66295

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	SAEZ et al. p95HER-2 predicts worse outcome in patients with HER-2-positive breast cancer. Clin Cancer Res 15 January 2006 Vol 12 No 2 Pages 424-431. Especially abstract.	1-33